The biotechnology arena’s financing total for 2015 reached unprecedented heights for the second straight year, according to EY’s 29th annual Beyond borders report. Biotech companies raised nearly $71 billion in 2015, well ahead of the previous record of $56 billion totaled during 2014.

Company to focus on pipeline of Pentarins™ as a unique and promising approach to treating solid tumor cancers Lead drug candidate PEN-221 targeting neuroendocrine and small cell lung cancers to advance into clinical studies in 2016   WATERTOWN, Mass.–(BUSINESS WIRE)–Tarveda Therapeutics, Inc., formerly Blend Therapeutics, today announced that it has secured $38 million in Series […]

CAMBRIDGE, Mass. – Celebrating its one-year anniversary since launching Unum Therapeutics, a company developing cellular immunotherapies for cancer treatment, took up new office space in one of the hottest real estate areas for pharma and biotech companies. The company opened a new 33,000 square-foot headquarters in Cambridge, Mass. and is expecting the new space will […]

January 27, 2016By Mark Terry, Breaking News Staff   Menlo Park, Calif.-based Adicet Bio, Inc. announced today that it had closed on a $51 million Series A financing round. The financing was led by OrbiMed and joined by Novartis Venture Fund and Pontifax. In addition, Adicet announced it had acquired Israeli company Applied Immune […]

November 20, 2015 By Alex Keown, Breaking News Staff SOUTH SAN FRANCISCO – A day after acquiring 70 percent of KaloBios (KBIO), Martin Shkreli, the embattled founder and chief executive officer of Turing Pharmaceuticals, has been named to the top spot of a company that was on the verge of shuttering. Company stock has […]

Venture-backed biotechs continue their blistering pace of funding. According to the latest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters, over $2.1B was invested in biotech companies in 2Q 2015, bringing the year to date total to almost $4B(covered here, here). Four of the last five quarters are amongst the largest record-setting […]

Cambridge, Mass.-based RaNA Therapeutics, Inc. , announced today that it had closed on a $55 million oversubscribed Series B financing round. Co-leading the round was MRL Ventures, the early-stage therapeutics fund of Merck & Co. (MRK), and The Baupost Group, LLC. Also participating were new investors Rock Springs Capital Management, Brookside Capital, Leerink Partners LLC […]